CEVEC, Yuhan sign CAP-Technology licensing deal

According to the deal, Yuhan can leverage CEVEC’s CAP-T and CAP cell expression systems in the production and development of a range of therapeutic proteins.

CEVEC CEO Wolfgang Kintzel said Yuhan selected CAP and CAP-T expression sytems as essential platform in the development of therapeutically relevant molecules.

"I’m convinced that the cells will have a major impact to develop more efficient biologics and will also shorten the timeline to enter clinical phases," Kintzel added.

CAP-T CAP cells are immortalized cell lines of non-tumor origin and exhibit high protein expression.

The cell lines, which were adapted to serum-free suspension culture, demonstrate human-like post-translational modifications such as authentic human glycosylation patterns.

Yuhan Research Institute the bio-innovation unit head Dr. Jong-Gyun Kim said, "We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it’s authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules."